Engraftment of human cells in PB, BM, and spleen at days 2, 7, and 16
Organ site . | Day 2 Mean ± SD, % . | Day 7 Mean ± SD, % . | Day 16 Mean ± SD, % . |
|---|---|---|---|
| PB | |||
| CD45+ | 11.9 ± 4.8 | 7.9 ± 3.6 | 66.3 ± 11.3 |
| CD4+ | 32.4 ± 1.5 | 39.4 ± 7.0 | 45.6 ± 3.0 |
| CD8+ | 52.2 ± 2.2 | 49.4 ± 6.3 | 38.6 ± 5.4 |
| CD4+CD8+ | 0.1 ± 0.1 | 0.3 ± 0.4 | 11.2 ± 1.3 |
| CD19+ | 4.8 ± 0.4 | 3.8 ± 1.8 | 0.2 ± 0.1 |
| CD14+ | 0.4 ± 0.4 | 0.0 ± 0.0 | 0.1 ± 0.0 |
| CD56+ | 14.6 ± 4.0 | 11.4 ± 3.2 | 2.9 ± 4.7 |
| BM | |||
| CD45+ | 1.4 ± 0.4 | 1.0 ± 0.7 | 8.1 ± 2.8 |
| CD4+ | 42.3 ± 9.2 | 57.6 ± 11.2 | 34.8 ± 7.9 |
| CD8+ | 33.0 ± 11.5 | 30.6 ± 13.2 | 23.8 ± 3.7 |
| CD4+CD8+ | 2.3 ± 2.5 | 1.0 ± 2.9 | 12.4 ± 3.2 |
| CD19+ | 12.0 ± 1.6 | 10.4 ± 7.5 | 30.0 ± 7.0 |
| CD14+ | 0.6 ± 0.9 | 2.2 ± 3.0 | 1.5 ± 1.0 |
| CD56+ | 1.8 ± 2.0 | 3.6 ± 3.4 | 0.2 ± 0.4 |
| Spleen | |||
| CD45+ | 9.1 ± 5.6 | 12.3 ± 4.9 | 81.6 ± 4.4 |
| CD4+ | 33.0 ± 10.2 | 28.0 ± 4.0 | 40.8 ± 7.3 |
| CD8+ | 52.0 ± 4.9 | 51.2 ± 4.0 | 32.2 ± 8.5 |
| CD4+CD8+ | 0.4 ± 0.9 | 2.6 ± 1.1 | 7.8 ± 1.5 |
| CD19+ | 7.2 ± 4.4 | 2.2 ± 1.8 | 11.8 ± 2.9 |
| CD14+ | 0.0 ± 0.0 | 0.6 ± 0.9 | 1.0 ± 0.6 |
| CD56+ | 6.4 ± 4.4 | 6.0 ± 2.6 | 0.1 ± 0.1 |
Organ site . | Day 2 Mean ± SD, % . | Day 7 Mean ± SD, % . | Day 16 Mean ± SD, % . |
|---|---|---|---|
| PB | |||
| CD45+ | 11.9 ± 4.8 | 7.9 ± 3.6 | 66.3 ± 11.3 |
| CD4+ | 32.4 ± 1.5 | 39.4 ± 7.0 | 45.6 ± 3.0 |
| CD8+ | 52.2 ± 2.2 | 49.4 ± 6.3 | 38.6 ± 5.4 |
| CD4+CD8+ | 0.1 ± 0.1 | 0.3 ± 0.4 | 11.2 ± 1.3 |
| CD19+ | 4.8 ± 0.4 | 3.8 ± 1.8 | 0.2 ± 0.1 |
| CD14+ | 0.4 ± 0.4 | 0.0 ± 0.0 | 0.1 ± 0.0 |
| CD56+ | 14.6 ± 4.0 | 11.4 ± 3.2 | 2.9 ± 4.7 |
| BM | |||
| CD45+ | 1.4 ± 0.4 | 1.0 ± 0.7 | 8.1 ± 2.8 |
| CD4+ | 42.3 ± 9.2 | 57.6 ± 11.2 | 34.8 ± 7.9 |
| CD8+ | 33.0 ± 11.5 | 30.6 ± 13.2 | 23.8 ± 3.7 |
| CD4+CD8+ | 2.3 ± 2.5 | 1.0 ± 2.9 | 12.4 ± 3.2 |
| CD19+ | 12.0 ± 1.6 | 10.4 ± 7.5 | 30.0 ± 7.0 |
| CD14+ | 0.6 ± 0.9 | 2.2 ± 3.0 | 1.5 ± 1.0 |
| CD56+ | 1.8 ± 2.0 | 3.6 ± 3.4 | 0.2 ± 0.4 |
| Spleen | |||
| CD45+ | 9.1 ± 5.6 | 12.3 ± 4.9 | 81.6 ± 4.4 |
| CD4+ | 33.0 ± 10.2 | 28.0 ± 4.0 | 40.8 ± 7.3 |
| CD8+ | 52.0 ± 4.9 | 51.2 ± 4.0 | 32.2 ± 8.5 |
| CD4+CD8+ | 0.4 ± 0.9 | 2.6 ± 1.1 | 7.8 ± 1.5 |
| CD19+ | 7.2 ± 4.4 | 2.2 ± 1.8 | 11.8 ± 2.9 |
| CD14+ | 0.0 ± 0.0 | 0.6 ± 0.9 | 1.0 ± 0.6 |
| CD56+ | 6.4 ± 4.4 | 6.0 ± 2.6 | 0.1 ± 0.1 |
Mice received clodronate-containing liposomes followed by 350 cGy irradiation and 10 × 106 huPBMCs. Fifteen mice were killed on days 2 (5 mice), 7 (5 mice), and 16 (5 mice). Human cells in PB, BM, and spleen were analyzed by FACS. Mean percentages ± standard deviations were calculated from the data of 5 mice for each measurement. The table shows engraftment of human CD45+ cells, CD4+/CD8+ T cells, B cells (CD19+), monocytes/macrophages (CD14+), and NK cells (CD56+CD3−).